JP2025514386A - 特定の化学物質、組成物、および方法 - Google Patents

特定の化学物質、組成物、および方法 Download PDF

Info

Publication number
JP2025514386A
JP2025514386A JP2024563863A JP2024563863A JP2025514386A JP 2025514386 A JP2025514386 A JP 2025514386A JP 2024563863 A JP2024563863 A JP 2024563863A JP 2024563863 A JP2024563863 A JP 2024563863A JP 2025514386 A JP2025514386 A JP 2025514386A
Authority
JP
Japan
Prior art keywords
pyridine
oxadiazol
fluoro
methyl
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514386A5 (enExample
Inventor
チェン，シャンピン（ショーン）
Original Assignee
ムルジャ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ムルジャ セラピューティクス，インク． filed Critical ムルジャ セラピューティクス，インク．
Publication of JP2025514386A publication Critical patent/JP2025514386A/ja
Publication of JP2025514386A5 publication Critical patent/JP2025514386A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024563863A 2022-04-27 2023-04-26 特定の化学物質、組成物、および方法 Pending JP2025514386A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263335687P 2022-04-27 2022-04-27
US63/335,687 2022-04-27
US202263403661P 2022-09-02 2022-09-02
US63/403,661 2022-09-02
PCT/US2023/066259 WO2023212612A2 (en) 2022-04-27 2023-04-26 Certain chemical entities, compositions, and methods

Publications (2)

Publication Number Publication Date
JP2025514386A true JP2025514386A (ja) 2025-05-02
JP2025514386A5 JP2025514386A5 (enExample) 2026-05-08

Family

ID=88519843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563863A Pending JP2025514386A (ja) 2022-04-27 2023-04-26 特定の化学物質、組成物、および方法

Country Status (7)

Country Link
US (1) US20250313556A1 (enExample)
EP (1) EP4514799A4 (enExample)
JP (1) JP2025514386A (enExample)
CN (1) CN119384421A (enExample)
AU (1) AU2023262139A1 (enExample)
CA (1) CA3250517A1 (enExample)
WO (1) WO2023212612A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4626884A1 (en) 2022-11-30 2025-10-08 Blueprint Medicines Corporation N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria
EP4630423A1 (en) * 2022-12-07 2025-10-15 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
CN122580315A (zh) * 2024-01-04 2026-08-14 上海翰森生物医药科技有限公司 多环类衍生物抑制剂、其制备方法和应用
WO2025255219A1 (en) * 2024-06-05 2025-12-11 Blueprint Medicines Corporation Crystalline forms of wild type kit inhibitors
TW202613112A (zh) * 2024-06-05 2026-04-01 美商纜圖藥品公司 野生型ｋｉｔ抑制劑
WO2025255295A1 (en) * 2024-06-06 2025-12-11 Blueprint Medicines Corporation Crystalline forms of wild type kit inhibitors
TW202613113A (zh) * 2024-06-11 2026-04-01 大陸商上海翰森生物醫藥科技有限公司 吡唑類衍生物抑制劑、其製備方法和應用
WO2025261494A1 (zh) * 2024-06-21 2025-12-26 上海美悦生物科技发展有限公司 一种稠杂环化合物、其制备方法和用途
WO2026026755A1 (zh) * 2024-07-30 2026-02-05 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200970447A1 (ru) * 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
CA2845785A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
WO2017098328A2 (en) * 2015-12-11 2017-06-15 Lifesci Phamaceuticals, Inc. Therapeutic inhibitory compounds
TW202237097A (zh) * 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法

Also Published As

Publication number Publication date
EP4514799A2 (en) 2025-03-05
WO2023212612A2 (en) 2023-11-02
WO2023212612A3 (en) 2023-12-07
US20250313556A1 (en) 2025-10-09
EP4514799A4 (en) 2026-04-22
CA3250517A1 (en) 2023-11-02
CN119384421A (zh) 2025-01-28
AU2023262139A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
AU2020343671C1 (en) RIP1 inhibitory compounds and methods for making and using the same
WO2023212612A2 (en) Certain chemical entities, compositions, and methods
CN112312904B (zh) 螺环化合物
USRE48731E1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US12247015B2 (en) 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
JP7395730B2 (ja) ヘテロ環式ｒｉｐ１阻害化合物
CA2871229C (en) Pyrrolopyridinone derivatives as ttx-s blockers
EP3679026A1 (en) Glutarimide
AU2018257203B2 (en) Novel tetrahydronaphthyl urea derivatives
CA2973773C (en) 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
JP7821811B2 (ja) ヤヌスキナーゼ阻害剤としてのヘテロ環誘導体
JP7763538B2 (ja) Ｐａｒｐ７阻害剤及びその使用
CN102656172A (zh) 8-氧代二氢嘌呤衍生物
US20250145599A1 (en) Certain chemical entities, compositions, and methods
JP2022551470A (ja) プロスタグランジンｅｐ４受容体アンタゴニスト化合物
US12521395B2 (en) Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors
JP2002348289A (ja) ３環性複素環化合物、その製造法および用途
CA3137584C (en) 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
CA3047580A1 (en) Compounds and methods for cdk8 modulation and indications therefor
MX2007000941A (en) Furanopyridine derivatives as ack1 and lck modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260424